Search hospitals > Texas > Dallas
Baylor University Medical Center
Claim this profileDallas, Texas 75246
Global Leader in Acute Myelogenous Leukemia
Global Leader in Multiple Myeloma
Conducts research for Acute Myeloid Leukemia
Conducts research for Breast Cancer
Conducts research for Heart Failure
357 reported clinical trials
17 medical researchers
Summary
Baylor University Medical Center is a medical facility located in Dallas, Texas. This center is recognized for care of Acute Myelogenous Leukemia, Multiple Myeloma, Acute Myeloid Leukemia, Breast Cancer, Heart Failure and other specialties. Baylor University Medical Center is involved with conducting 357 clinical trials across 601 conditions. There are 17 research doctors associated with this hospital, such as Joyce O'Shaughnessy, MD, Carlos R Becerra, Susan Mathai, MD, and Andrew S Paulson, MD.Area of expertise
1Acute Myelogenous Leukemia
Global LeaderKMT2A positive
NPM1 positive
NPM1c positive
2Multiple Myeloma
Global LeaderStage III
del(17/17p) positive
t(14;16) positive
Top PIs
Joyce O'Shaughnessy, MDTexas Oncology-Baylor Charles A. Sammons Cancer Center8 years of reported clinical research
Expert in Breast Cancer
Studies Pancreatic Cancer
20 reported clinical trials
37 drugs studied
Carlos R BecerraGSK Investigational Site2 years of reported clinical research
Studies Solid Tumors
Studies Lung Cancer
6 reported clinical trials
10 drugs studied
Susan Mathai, MDBaylor Scott & White Research Institute1 year of reported clinical research
Studies Idiopathic Pulmonary Fibrosis
Studies Interstitial Lung Disease
5 reported clinical trials
7 drugs studied
Andrew S Paulson, MDTexas Oncology - Baylor Charles A. Sammons Cancer Center2 years of reported clinical research
Studies Colorectal Cancer
Studies Neuroendocrine Tumors
5 reported clinical trials
9 drugs studied
Clinical Trials running at Baylor University Medical Center
Multiple Myeloma
Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease
Lymphoma
Non-Hodgkin's Lymphoma
Post-Traumatic Stress Disorder
Heart Failure
Acute Myeloid Leukemia
Pulmonary Hypertension
Crohn's Disease
Elranatamab Combinations
for Multiple Myeloma
The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone, and (2) learn about the safety and activity of elranatamab in combination with the anti-CD38 monoclonal antibody daratumumab. People with multiple myeloma who have received previous treatment including lenalidomide will be enrolled in the study. Part 1 of the study will assess the safety and activity of different doses of elranatamab in combination with daratumumab. People participating in Part 2 of the study will be randomly assigned to receive either elranatamab alone, elranatamab plus daratumumab, or daratumumab, pomalidomide, and dexamethasone. Part 2 will evaluate the safety and activity of (1) elranatamab alone compared to daratumumab, pomalidomide, and dexamethasone, and (2) elranatamab plus daratumumab. Part 3 will assess the effect of increased measures to protect against infection in people treated with either elranatamab alone or together with daratumumab. All people participating in the study will receive study treatment until their disease progresses, they experience unacceptable side effects, or they choose to no longer participate in the study.
Recruiting2 awards Phase 36 criteria
Elranatamab
for Multiple Myeloma
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments before for MM. * Have MM that has returned or not responded to their most recent treatment. Half of the participants will receive elranatamab. The other half of participants will receive a combination therapy selected by the study doctor. The selected combination therapy will include 2 to 3 different medicines commonly used to treat MM. Elranatamab will be given as a shot under the skin at the study clinic about once a week. This may change to a smaller number of shots later in the study. The medicines in the combination therapy will be taken by mouth (at home or at the study clinic) AND will be given either as: * a shot under the skin at the study clinic * through a needle in the vein at the study clinic The number of times these medicines will be taken depends on what combination therapy the study doctor selects. Participants may continue to receive elranatamab or a combination therapy until their MM is no longer responding. The study team will see how each participant is doing with the study treatment during regular visits at the study clinic. The study team will continue to follow-up with participants after study treatment with telephone contacts (or visits). The study will compare the experiences of people receiving elranatamab to those people receiving a combination therapy. This will help learn about the safety and how effective elranatamab is.
Recruiting2 awards Phase 36 criteria
Elranatamab vs Lenalidomide
for Multiple Myeloma
The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be approximately five years
Recruiting2 awards Phase 38 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Baylor University Medical Center?
Baylor University Medical Center is a medical facility located in Dallas, Texas. This center is recognized for care of Acute Myelogenous Leukemia, Multiple Myeloma, Acute Myeloid Leukemia, Breast Cancer, Heart Failure and other specialties. Baylor University Medical Center is involved with conducting 357 clinical trials across 601 conditions. There are 17 research doctors associated with this hospital, such as Joyce O'Shaughnessy, MD, Carlos R Becerra, Susan Mathai, MD, and Andrew S Paulson, MD.
Where is Baylor University Medical Center located?
**Baylor University Medical Center, Dallas, Texas**
- **Address:** 3500 Gaston Ave, Dallas, TX 75246
- **Location:** Near the intersection of Gaston Avenue and Junius Street.
- **Parking:** Multiple parking garages and valet services available.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Baylor University Medical Center, contact Eligibility and Enrollment Services at 972.892.3026. For insurance inquiries, visit the Insurance office next to the registration desk in the Medical Clinic, 2nd floor of the McLane Student Life Center, or contact them at 254-710-7425. Address correspondence to Baylor University Health Services Insurance Office, One Bear Place #97060, Waco, TX 76798.
What insurance does Baylor University Medical Center accept?
The Baylor University Medical Center accepts a wide range of insurance plans, including Traditional Medicaid, Traditional Medicare, and any Medicare Supplement/Medigap plan not tied to a network. They are also contracted providers for various insurance companies and networks, including Aetna, Blue Cross Blue Shield, Cigna HealthCare, and Humana. It's important to confirm coverage with your insurance provider before scheduling any visits or procedures.
What awards or recognition has Baylor University Medical Center received?
Baylor University Medical Center in Dallas, Texas, is renowned for its exceptional maternity services, earning a Level IV Maternity designation and ranking among the nation's top 50 gynecology programs by U.S. News and World Report. The hospital offers advanced wound care, including hyperbaric oxygen therapy and specialized treatments for hard-to-heal wounds. In 2022, it received over $15 million in grants, supported by the Baylor Scott & White Dallas Foundation and Dallas Safety Net Support Corporation, enhancing patient care, education, medical research, and community service.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.